Genetic markers for head and neck cancers - Current state of art and perspectives;Genski markeri karcinoma glave i vrata - Savremena saznanja i perspektive

Jugoslovenska Medicinska Biohemija

Volumn 22, Issue 4, 2003, Pages 273-282

  Dukić, Vojko ^a,b   Janošević, Ljiljana ^b   Dimitrijević, Milovan ^b   Damjanović, Svetozar ^b   Peško, Predrag ^b   Dotlić, Jelena ^b  

^a CLINICAL CENTER OF SERBIA   (Serbia)

^b Institute of Pathology   (Serbia)

Author keywords

Genetic markers; Head and neck cancers

Indexed keywords

COLLAGEN TYPE 7; CYCLIN D1; DNA; MEMBRANE ANTIGEN; NUCLEIC ACID; PLASMA PROTEIN; PROTEIN P53; RNA; UVOMORULIN; VASCULOTROPIN;

CANCER PREVENTION; CANCER RECURRENCE; CANCER SURVIVAL; CELL SURFACE; CLINICAL PRACTICE; GENE AMPLIFICATION; GENE STRUCTURE; GENETIC MARKER; HEAD AND NECK CANCER; HORMONE SYNTHESIS; HUMAN; METASTASIS; MOLECULAR BIOLOGY; PHENOTYPE; POLYMERASE CHAIN REACTION; PRECANCER; PROTEIN SYNTHESIS; REVIEW; SOMATIC CELL; TUMOR CELL;

EID: 0344253732     PISSN: 03543447     EISSN: None     Source Type: Journal    
DOI: 10.2298/JMH0304273D     Document Type: Review

References (66)

1. Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184-97.
2. Swango PA. Cancers of the oral cavity and pharynx in the United States: an epidemiological overview. J Public Health Dent 1996; 56: 309-18.
3. Fonseca RJ. Oral and Maxillofacial Surgery. Surgical pathology 2001; 5: 52-62.
4. Knowles JE. Early diagnosis and treatment of head and neck cancer. J Maine Med Assoc 1971; 62 (9): 217-8.
5. Norris CW. Metastatic cancer. Diagnosis: head and neck cancer. J Kans Med Soc 1972; 73 (3): 116-9.
6. Shaw HJ. Early diagnosis of cancer of the head and neck. Br Med J 1976 Feb 14; 1 (6006): 379-83.
7. McGuff HS, Otto RA, Aufdemorte TB. Clinical warning signs and symptoms of head and neck cancer. Tex Dent J 2000; 117 (6): 14-9.
8. Kao GD, Rudoltz M. Staging of head and neck cancer. N Engl J Med 1995 Jan 29; 332 (26): 1788-9.
9. Ballester M. Quoi de neuph? Recherche contra le cancer: advancées et perspectives. Rev Laryngol Otol Rhinol 2002; 4: 267-68.
10. Filipović S. Klinički značaj tumorskih markera u ranoj dijagnostici i praćenju progresije malignih bolesti. U: Klinička imunologija 2. Ljaljević J ur ECPD, 2002, 1195-1208.
11. Cooner WH. Definition of the ideal tumor marker. Urol North Am 1993; 4: 475-579.
12. Gamulin S, Marušić M, Krvavica S i sar, Patofiziologija. Medicinska naklada 1995; 431-54.
13. Piessens WF, David J. Tumor immunology. In: Scientific American Medicine. Rubenstein E, Federman DD. Scientific American New York, 1995 6/VIII, 1-11.
14. Saunders JR Jr. The genetic basis of head and neck carcinoma. Am J Surg 1997; 174 (5): 459-61.
15. Greenberg PD. Mechanisms of tumor immunology. In: Medical Immunology. Stites DP, Terr AI, Parslow TG. ers. Appleton and Lange, Stamford, Connecticut. 1997; 631-77.
16. Rubenstein E, Federman DD. Scientific American Medicine 2: Oncology; Sceintific American New York, 1995.
17. Springer GF. T and Tn, general carcinoma antigens. Science 1984; 224: 1198.
18. Friedlander PL. The use of genetic markers in the clinical care of patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2003; 129: 363-66.
19. Nikoliš J. Genetska osnova kancerogeneze. U: Osnovi onkologije. Jančić-Zguricas M, Spužić I. urs. Elit Medica. Beograd, 1995; 17-31.
20. Grabenbauer GG. Predictive and prognostic significance of PCNA, p53, bcl-2 and intratumor vessel density in radiochemotherapy of advanced head and neck tumors. Strahlenther Onkol 1997; 173 (3): 174-5.
21. Lopez-Martinez M, Anzola M, Cuevas N, Aguirre JM, DePancorbo M. Clinical applications of the diagnosis of p53 alterations in squamous cell carcinoma of the head and neck. Med Oral 2002; 7 (2):108-20.
22. Gottschlich S, Folz BJ, Goeregh T, Lippert BM, Maass JD, Werner JA. A new prognostic indicator for head and neck cancer - p53 serum antibodies? Anticancer Res 1999; 19 (4A): 2703-5.
23. Hauser U, Balz V, Carey TE, Grenman R, Van Lierop A. Schsckenbach K. Bier H. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 2002 24 (9): 868-73.
24. Silva JM, Bonilla F. Correspondence re: F. Coulet et al., Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Res 2000; 60: 707-9.
25. Nylander K, Dabelsteen E, Hall PA. The p53 molecule and its prognostic role in squamous cell carcinoma of head and neck. J Oral Pathol Med 2000; 29 (9): 413-25.
26. Quon H, Liu FF, Cummings. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 147-159.
27. Rodrigo Tapia JP, Gonzalez Meana MV, Garcia Gonzalez LA, Coto E, Garcia Pedrero J, Nunez Batalla F, Suarez Nieto C. Inactivation of p53 and amplification of cyclin D1 in squamous cell carcinomas of the head and neck. Acta Otorrinolaryngol Esp 2002; 53 (4): 225-32.
28. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma (SCCHN): 1.Cancerogen metabolism, DNA repair and cell cycle control. Oral Oncol 2000; 36 (3): 256-63.
29. Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol 2000; 36 (4): 311-27.
30. Oh Y, Mao L. Biomarkers in head and neck carcinoma. Curr Opin Oncol 1997; 9 (3): 247-56.
31. Partrige M. Head and neck cancer and precancer: can we use molecular genetics to make better predictions? Ann R Coll Surg Engl 1999; 81 (1): 1-11.
32. Partridge M. Oral cancer: 2. Clinical presentation and use of new knowledge about the biology of cancer to establish why tumors may recur. Dent Update 2000; 27 (6): 288-94.
33. Kozomara R. Značaj p53 antionkogena i humanog papiloma virusa za radiorezistenciju planocelularnog karcinoma jezika i poda usta. Doktorska disertacija. Vojnomedicinska akademija. Beograd, 2003.
34. Charuruks N, Shin DM, Voravud N, Ro Jy, Hong WK, Hittelman WN. P53 expression and polysomies of chromosome 9, 17 in head and neck cancer prognosis. J Med Assoc Thai 1999; 82 (5): 466-76.
35. Rodrigo JP, Coto E, Gonzalez MV, Maldonado M, Suarez C. P53 allelic loss and outcome in patients with squamous cell carcinoma of the head and neck. Eur Arch Otorhinolaryngol 2001; 258 (5): 255-8.
36. Alsner J, Hoyer M, Sorensen SB, Overgaard J. Interaction between potential doubling time and TP53 mutation: predict radiotherapy outcome in squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2001 Feb 1; 49 (2): 519-25.
37. Liao PH, Chang YC, Huang MF, Tai KW, Chou MY. Mutations of p53 gene codon 63 in saliva as molecular marker for oral squamous cell carcinoma. Oral Oncol 2000; 36 (3): 272-6.
38. Field JK, Spindidos DA, Stell PM. Overexpression of the p53 gene in head and neck cancer, linked with heavy smoking and drinking. Lancet 1992 Feb 22; 330 (8791): 502-3.
39. Kapranos N, Stathopoulos GP, Manolopoulos L, Kokka E, Papadimitriou C, Bibas A, Yiotakis J, Adamopoulos G. P53, p23 i p27 protein expession in head and neck cancer and their prognostic value. Anticancer Res 2001; 21 (1B): 521-8.
40. Adamiak G, Ligezinski A, Jurkiewicz D, Hermanowski M, Konieczna M. Alpha-fetoprotein - diagnostic utility in squamous cell carcinoma of the head and neck. Pol Merkuriusz Lek 2001; 11(64): 320-2.
41. Rodel C. The amplification of 11q13DNA markers in squamous-cell carcinoma in the head-neck area: a correlation with the clinical course. Stahlenther Oncol. 1998; 174 (12): 642-3.
42. Kudo Y, Takata T, Ogawa I, Zhao M, Sato S, Takekoshi T et al. Reduced expression of p27 (Kip1) correlates with an early stage of cancer invasion in oral squamous cell carcinoma. Cancer Lett 2000; 14 (151): 217-22.
43. Yarbrough WG, Buckmire RA, Bessho M, Liu ET. Biologic and biochemical analysis of p16 (INK4a) mutations from primary tumors. J Natl Cancer Inst 1999; 91: 1569-1574.
44. Van der Toom PPG, Veltman JA, Bot FJ, de Jong JMA, Manni JJ, Ramaekers FCS et al. Mapping of resection margins of oral cancer for p53 overexpression and chromosome instability to detect residual (pre)malignant cells. J Patol 2001; 193: 66-72.
45. Van-Oijen MG, Leppers VD, Stratt FG, Tilanus MG, Slootweg PJ. The origin of multiple squamous cell carcinomas in the aerodigestive tract. Cancer 2000; 15 (88): 884-93.
46. Lopes MA, Nikitakis N, Reynolds MA, Ord RA, Sauk J. Biomarkers predictive of lymph node metastasis in oral squamous cell carcinoma. Americ Asssociat Oral MaxFac Surg 2002; 60: 142-8.
47. Osaki T, Kimura T, Tatemoto Y, Yamamoto T, Yoneda K. Risk factors of metastasis in oral squamous cell carcinomas. Oncology 2000; 58: 137-43.
48. Calias G, Alfonsi M, Bardet E et al. Randomised trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Nalt Cancer Inst 1999; 91: 2081-6.
49. Trask DK, Wolf GT, Bradford CR, et al. Expressions of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: corelation with response to chemotherapy and organ preservation. Laryngoscope 2002; 112: 638-44.
50. Flis MS, Usadel H, Cabellero OL, Wu L, Buta MR, Eleff SM et al. Facile detection of mitochondrial DNA mutations in tumors and body fluids. Science 2000; 287: 2117-19.
51. Huang H, Li CY, Little JB. Abrogation of p53 function by transfection of HPV 16 E6 gene does not enhance resistence of human tumor cell to ionizing radiation. Int J Radiat Biol 1996; 70: 151-60.
52. Koch W. Genetic markers in the clinical care of head and neck cancer. Slow in coming. Arch Otolaryngol Head Neck Surg 2003; 129: 367-68.
53. De Bree R, Deurloo EE, Snow GB, Lemans CR. Screening for distant metastasis in patient with head and neck cancer. Laryngoscope 2000; 110: 397-401.
54. Van Houten VM, Tabor MP, van den Brekel MW, et al. Molecular assays for the diagnosis of minimal residual head-and-neck cancer; methods, realiability, pitfalls and solutions. Clin Cancer Res 2000; 6: 3803-16.
55. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D. Microsatellite alterarions in serum DNA of head and neck cancer patients. Nat Med 1996; 2: 1035-37.
56. Van Houten VM, van den Brekel MW, Denkers F, et al. Molecular diagnosis of head and neck cancer. Recent Results Cancer Res 2000; 157: 90-106.
57. Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathologic staging in squamous cell carcinoma of the head and neck. N Engl J Med 1995; 332: 429-35.
58. Sturgis EM, Miller RH. Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol 1995; 104: 946-54.
59. Papadimitrakopoulou VA, Clayman GL, Shin DM, et al. Biocchemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg. 1999; 125: 1083-89.
60. Clayman GL, Frank DK, Bruso PA, Goepfert H. Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res 1999; 1715-22.
61. Nemunaitis J, Khuri F, Ganly I, et al. Phase 11 trial on intratumoral administration of ONYX-015, a replication-selective adenovirus, in patient with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-98.
62. Gleich LL, Glukman JL, Nemunatis J, et al. Clinical experience with HLA-B7 plasmid DNA/lipidcomplex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001; 775-9.
63. Dassonville O, Formento JL, Francoual M, et al. Expression of epithelial growth factor receptor and survival in the upper aerodigestive tract cancer. J Clin Oncol 1993; (11): 1873-8.
64. Robert F, Eyekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combinationwith radiation therapy in patients wizh advanced cancer. J Clin Oncol 2001; 19: 3234-43.
65. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor - targeted therapy with C225 and cisplatin in patients eizh head and neck cancer. Clin Cancer Res 2001; 7: 1204-13.
66. Bredford CR. Genetic markers of head and neck cancer. Identifying new molecular targets. Arch Otolaryngol Head Neck Surg 2003; 129: 366-7.